MARC2 anticorps (AA 270-300)

N° du produit ABIN7873150

Cet anticorps anti-MARC2 Polyclonal Lapin (ABIN7873150) détecte spécifiquement MARC2 dans WB, IHC (p) et FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour MARC2 anticorps (AA 270-300) (ABIN7873150)

Antigène: MARC2 (Mitochondrial Amidoxime Reducing Component 2 (MARC2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MARC2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS)

Détail du produit anti-MARC2 anticorps

Épitope: AA 270-300

Fonction: Mitochondrial amidoxime reducing component 2 Antibody / mARC2 / MTARC2

Purification: Antigen affinity purified

Immunogène: A portion of amino acids 270-300 from the human protein was used as the immunogen for the Mitochondrial amidoxime reducing component 2 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: The stated application concentrations are suggested starting points. Titration of the Mitochondrial amidoxime reducing component 2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the Mitochondrial amidoxime reducing component 2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur MARC2

Antigène: MARC2 (Mitochondrial Amidoxime Reducing Component 2 (MARC2))

Autre désignation: Mitochondrial amidoxime reducing component 2

Sujet: Catalytic component of the benzamidoxime prodrug-converting complex, a complex required to reduce N-hydroxylated structures, such as benzamidoxime prodrug. Benzamidoxime is an amidine prodrug produced by N-hydroxylation which is used to enhance bioavailability and increase intestinal absorption. It is then reduced into benzamidine, its active amidine, by the benzamidoxime prodrug-converting complex.

UniProt: Q969Z3